{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-074330","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.814641+00:00","generated_at":"2026-05-17T15:35:23.466134+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"CEO presents Pearsanta IPO plans; commercialization target Q1 2026","bullets":["CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.","Pearsanta's cancer diagnostics platform uses mitochondrial DNA blood tests; initial targets prostate cancer and endometriosis.","Commercial launch of first tests targeted for end of 2025 / Q1 2026 after validation studies.","Pearsanta IPO planned for early first half 2026 with Spartan Capital as underwriter.","Aditxt strategy: acquire health innovations, build in-house, monetize via events like Pearsanta IPO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-074330","json":"https://secwatch.observer/filing/0001213900-25-074330.json","markdown":"https://secwatch.observer/filing/0001213900-25-074330.md","text":"https://secwatch.observer/filing/0001213900-25-074330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025074330/0001213900-25-074330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025074330/ea0252550-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:35:23.466134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}